Rhythm Biosciences LimitedASX: RHY

Rhythm Appoints Adam Zembrzuski as Chief Commercial Officer

· Issued by Rhythm Biosciences Limited via ASX

Filed with ASX · · 3 pages · English

Summary by 6ix AI

Rhythm Biosciences Limited has appointed Adam Zembrzuski as Chief Commercial Officer, effective soon. Mr. Zembrzuski brings extensive experience in clinical diagnostics and will lead the company's global commercial growth strategy. His role includes overseeing the commercial strategy for existing products and expanding market access. The announcement highlights the company's focus on accelerating revenue growth and increasing clinical adoption of its diagnostic platforms.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

ASX Announcement 17 November 2026 Rhythm Appoints Adam Zembrzuski as Chief Commercial Officer Highlights ? Rhythm has appointed Adam Zembrzuski as Chief Commercial Officer (CCO), effective 18 November 2026 ? Adam brings 21 years’ commercial leadership experience in clinical diagnostics, medical...

Rhythm Biosciences Limited on 6ix

Story so far

Earlier from Rhythm Biosciences

All Rhythm Biosciences news releases